Review
Oncology
Johannes P. W. Heidbuechel, Christine E. Engeland
Summary: Bispecific T cell engagers (BiTEs) and oncolytic viruses (OVs) are emerging cancer immunotherapies that redirect T cells to tumor surface antigens and selectively infect malignant cells to mediate tumor vaccination effects, respectively. These two approaches can synergize with each other and with other immunotherapies, such as CAR T cells and immune checkpoint inhibitors, to enhance anti-tumor effects.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Yunmeng Wang, Ping Cheng
Summary: Oncolytic viruses (OVs) are emerging as therapeutically relevant anticancer agents, especially when combined with genetically modified bispecific T cell engagers (BiTEs). This combination strategy can overcome the limitations of BiTEs alone and provide targeted cytotoxicity to solid tumors.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Review
Oncology
Qi Huang, Wen-Qi Cai, Zi-Wen Han, Mo-Yu Wang, Yang Zhou, Jun-Ting Cheng, Ying Zhangl, Ying-Ying Wang, Qiang Xin, Xian-Wang Wang, Xiao-Chun Peng, Ying Xiang, Shu-Xian Fang, Zhao-Wu Ma, Hong-Yi Xing, Shu-Zhong Cui, Hong-Wu Xin
Summary: In tumor immunotherapy, BiTE and OV-BiTE demonstrate synergistic therapeutic effects, offering new avenues for cancer treatment. Recent research and clinical trials indicate that OV-BiTE holds promising potential as an exciting platform in tumor immunotherapy.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Divya Ravirala, Brandon Mistretta, Preethi H. Gunaratne, Guangsheng Pei, Zhongming Zhao, Xiaoliu Zhang
Summary: Novel chimeric molecules, BiCEP and TriCEP, were constructed and evaluated in this study for their ability to engage both NK and T cells, enhancing antitumor activities. Both molecules showed promising results in engaging immune cells to kill tumor cells, suggesting their potential in oncolytic virotherapy for cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Pharmacology & Pharmacy
Seyed-Mahmood Seyed-Khorrami, Arezou Azadi, Nasrin Rastegarvand, Ala Habibian, Hoorieh Soleimanjahi, Marek J. Los
Summary: Immunotherapy and virotherapy have emerged as new methods for cancer treatment, with better specificity and outcomes. Applying these strategies in the treatment of malignancies is of great significance, based on advances in understanding cancer cell biology and oncolytic viruses.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Oncology
Mirco J. Friedrich, Paola Neri, Niklas Kehl, Julius Michel, Simon Steiger, Michael Kilian, Noemie Leblay, Ranjan Maity, Roman Sankowski, Holly Lee, Elie Barakat, Sungwoo Ahn, Niels Weinhold, Karsten Rippe, Lukas Bunse, Michael Platten, Hartmut Goldschmidt, Carsten Mueller-Tidow, Marc-Steffen Raab, Nizar J. Bahlis
Summary: Bispecific T cell engagers (TCEs) have shown promise in treating various cancers, but the immune mechanisms and molecular determinants of resistance to TCEs are still poorly understood. This study identifies conserved behaviors of bone marrow-residing T cells in multiple myeloma patients undergoing BCMAxCD3 TCE therapy and reveals the association between tumor recognition, exhaustion, and clinical response. The findings also highlight the significance of targeting exhausted-like CD8+ T cells and the loss of target epitope and MHC class I in tumor adaptation to TCEs. These insights advance our understanding of TCE treatment in humans and provide a basis for immune-monitoring and immunotherapy in hematological malignancies.
Review
Oncology
Kirit Singh, Kelly M. Hotchkiss, Aditya A. Mohan, Jessica L. Reedy, John H. Sampson, Mustafa Khasraw
Summary: Glioblastoma is the most common primary brain tumor in adults with a uniformly lethal prognosis. While immunotherapies have not shown significant clinical benefit in treatment, bispecific T-cell engagers are promising antibody fragment therapies. However, the challenges posed by the tumor microenvironment, immune privilege, and blood-brain barrier suggest that a single agent approach may be insufficient for lasting antitumor efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Xin-Ying Tang, Yu-Shi Ding, Tao Zhou, Xu Wang, Yong Yang
Summary: CAR-T cell therapy has shown promising results in hematologic malignancies, but its efficacy in solid tumors is limited due to antigen heterogeneity, suboptimal trafficking, and immunosuppressive microenvironment. Combination with oncolytic viruses (OV) might be a novel solution to overcome these challenges and improve the therapeutic outcomes for non-hematologic malignancies.
Article
Chemistry, Multidisciplinary
Wei-Jie Cheng, Kuo-Hsiang Chuang, Yu-Ju Lo, Michael Chen, Yi-Jou Chen, Steve R. Roffler, Hsiu-O Ho, Shyr-Yi Lin, Ming-Thau Sheu
Summary: In this study, a biocompatible nanocarrier system loaded with ganetespib was developed to enhance the efficacy of immunotherapies. The system, decorated with bispecific T-cell engagers, showed increased cellular uptake and synergistic effects in T cell-mediated cytotoxicity. In vivo studies also demonstrated tumor growth inhibition and increased T-cell infiltration. This study provides a promising drug delivery strategy for cancer immunochemotherapy.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Oncology
Zheng Tian, Ming Liu, Ya Zhang, Xin Wang
Summary: Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. Bispecific antibodies such as BiTEs have shown potential in recruiting T cells to tumor cells for immunotherapy, with a focus on improving efficacy and safety in clinical treatments for hematologic malignancies.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Ling Zhang, Seyed Abbas Pakmehr, Reza Shahhosseini, Maryam Hariri, Azadeh Fakhrioliaei, Farid Karkon Shayan, Wenxue Xiang, Sepideh Karkon Shayan
Summary: The immunosuppressive tumor microenvironment (TME) hinders the effectiveness of ICIs and CAR T-cell therapy in solid tumor treatment. Oncolytic virotherapy (OV) shows potential in reprogramming TME and improving the therapeutic outcomes of solid tumors.
Article
Biochemistry & Molecular Biology
Aleksandra Rodak, Gerhard Stadlmayr, Katharina Stadlbauer, Dominic Lichtscheidl, Madhusudhan Reddy Bobbili, Florian Rueker, Gordana Wozniak-Knopp
Summary: The study of IgE is important in the treatment of allergies and asthma, and therapeutic anti-IgE antibodies can intervene in its function by different mechanisms to reduce serum IgE levels. Bispecific antibody fusion proteins have shown promising results in eliciting cytotoxic T-cell-mediated killing through specific activation.
Article
Oncology
Shiyu Liu, Fan Li, Li Deng, Qiongqiong Ma, Wenyi Lu, Zhuoqian Zhao, Huanzhen Liu, Yixuan Zhou, Manli Hu, Hui Wang, Yingbin Yan, Mingfeng Zhao, Hongkai Zhang, Mingjuan Du
Summary: The combination of bispecific T cell engagers (BiTEs) and oncolytic viruses (OVs) has shown promising results in the treatment of pancreatic cancer, improving the tumor microenvironment, enhancing immune response, and inhibiting tumor growth.
MOLECULAR THERAPY-ONCOLYTICS
(2023)
Review
Cell Biology
Hadi Esmaeili Gouvarchin Ghaleh, Gazal Vakilzadeh, Ali Zahiri, Mahdieh Farzanehpour
Summary: Mesenchymal stem cells (MSCs) have the unique ability to migrate to tumors, which makes them an excellent candidate for targeted delivery of oncolytic viruses (OVs) to treat cancer. OVs selectively infect and destroy tumor cells while sparing normal cells, and they can induce immunogenic cell death and contain curative transgenes. When combined with MSCs, OVs can modulate the tumor microenvironment and trigger anti-tumor immune responses, offering a promising approach for cancer treatment.
CELL COMMUNICATION AND SIGNALING
(2023)
Article
Oncology
Jeong A. Park, Madelyn Espinosa-Cotton, Hong-fen Guo, Sebastien Monette, Nai-Kong Cheung
Summary: This study demonstrates that using anti-VEGF antibodies can significantly improve the therapeutic efficacy of T cell immunotherapies by increasing HEVs and promoting the infiltration of cytotoxic CD8(+) TILs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy, Len W. Seymour
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2018)
Review
Biotechnology & Applied Microbiology
Arthur Dyer, Richard Baugh, Suet Lin Chia, Sally Frost, Iris, Egon J. Jacobus, Hena Khalique, Tzveta D. Pokrovska, Eleanor M. Scott, William K. Taverner, Len W. Seymour, Janet Lei
CANCER GENE THERAPY
(2019)
Article
Oncology
Joshua D. Freedman, Margaret R. Duffy, Janet Lei-Rossmann, Alice Muntzer, Eleanor M. Scott, Joachim Hagel, Leticia Campo, Richard J. Bryant, Clare Verrill, Adam Lambert, Paul Miller, Brian R. Champion, Leonard W. Seymour, Kerry D. Fisher
Article
Oncology
Arthur Dyer, Benjamin Schoeps, Sally Frost, Philip Jakeman, Eleanor M. Scott, Joshua Freedman, Egon J. Jacobus, Leonard W. Seymour
Article
Cell & Tissue Engineering
Si-Yuen Lee, Julian H. George, David A. Nagel, Hua Ye, Gray Kueberuwa, Leonard W. Seymour
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
(2019)
Article
Oncology
Iris Yousaf, Jakob Kaeppler, Sally Frost, Len W. Seymour, Egon J. Jacobus
Article
Oncology
Tzveta D. Pokrovska, Egon J. Jacobus, Rathi Puliyadi, Remko Prevo, Sally Frost, Arthur Dyer, Richard Baugh, Gonzalo Rodriguez-Berriguete, Kerry Fisher, Giovanna Granata, Katharine Herbert, William K. Taverner, Brian R. Champion, Geoff S. Higgins, Len W. Seymour, Janet Lei-Rossmann
Review
Oncology
Richard Baugh, Hena Khalique, Leonard W. Seymour
Review
Oncology
Kerry Fisher, Ahmet Hazini, Leonard W. Seymour
Summary: Oncolytic viruses hold promise in cancer therapy by lysing cancer cells and stimulating immune responses, but antigen presentation dysregulation can lead to immune escape. Understanding and measuring key immunological factors can optimize the use of oncolytic viruses for effective treatment.
Review
Oncology
Ahmet Hazini, Kerry Fisher, Len Seymour
Summary: Tumors undergo clonal selection, leading to the expression of tumor antigens in a subset of tumor cells. Immunosurveillance exerts selective pressure by eliminating tumor cells expressing recognized antigens by T cells, and may also select for tumor cells that evade immune detection by acquiring deficiencies in their HLA presentation pathways.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Multidisciplinary Sciences
Weiheng Su, Maria I. Patricio, Margaret R. Duffy, Jakub M. Krakowiak, Leonard W. Seymour, Ryan Cawood
Summary: The authors describe a self-inhibiting helper plasmid strategy that improves outcomes compared to helper-free approaches.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Si-Yuen Lee, Julian George, David Nagel, Hua Ye, Leonard Seymour
Summary: This study proposed a 3D platform based on RGD-alginate for encapsulating optogenetically modified human neuronal cells, demonstrating their survival and ability to express functional neurons.